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Histologic variants of idiopathic focal segmental
glomerulosclerosis (FSGS) may have prognostic value. A
recent working classification system has distinguished five
FSGS variants. We evaluated a cohort of adult patients with
biopsy-proven FSGS diagnosed between March 1982 and
July 2001 to determine if subtypes were associated with renal
outcome. Renal biopsies were reviewed by two pathologists.
Demographic and clinical data were obtained from charts.
Outcomes were partial and complete remission of the
nephrotic syndrome, and renal failure. The frequency of FSGS
variants was: 3% cellular (N¼ 6), 11% collapsing (N¼ 22),
17% tip lesion (N¼ 34), 26% perihilar (N¼ 52), and 42% not
otherwise specified (NOS) (N¼ 83). Collapsing FSGS affected
younger and more often black patients. Black race was
uncommon in tip variant. Collapsing and tip variants had
higher proteinuria and lower serum albumin than perihilar
and NOS variants. Better renal function and less severe
tubulointerstitial injury were observed in patients with tip
variant. These patients were more likely to receive steroids
and more often achieved complete remission (50%). After a
median follow-up of 1.8 years, 23% of patients were on
dialysis and 28% had renal failure. Collapsing FSGS had worse
1-year (74%) and 3-year (33%) renal survival compared to
other variants (overall cohort renal survival at 1 and 3 years:
86 and 67%). Different histologic variants of FSGS have
substantial differences in clinical features at the time of
biopsy diagnosis and substantial differences in renal
outcomes.
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The term focal segmental glomerulosclerosis (FSGS) is
applied to a pathologically diverse group of glomerular
lesions with heterogeneous clinical manifestations. FSGS
shares overlapping patterns of injury with segmental
consolidation and obliteration of glomerular architecture
by accumulation of collagenous extracellular matrix or by
increased cellularity or both. Different studies report a broad
range of estimates for progression to renal failure, remission
rates of the nephrotic syndrome, and response to therapy of
patients with FSGS.1–3
Differences in study populations, such as racial profile or
therapy, may explain some of the discrepancies in outcomes
between different clinical studies. However, the differences
can be, in part, the result of the failure to recognize the
structural variants of FSGS and to stratify the data
accordingly. Recognition of unique subtypes of FSGS may
be required because the histopathologic variants of FSGS
could be etiologically and pathogenetically distinct, and
therefore have different prognoses and optimum therapies.
For example, the tip lesion variant of FSGS (tip lesion FSGS),
initially described by Howie et al. in 1984, may have a more
benign course and a better response to corticosteroid therapy
compared to other structural variants of FSGS.4–9 Conversely,
the collapsing variant of FSGS (collapsing FSGS) is known for
an aggressive course, often with decreased renal function at
presentation and rapid progression to renal failure.10,11 The
perihilar variant of FSGS (perihilar FSGS) usually is
accompanied by glomerulomegaly and often is seen in
association with obesity or reduced functional renal mass.12
Most studies of the clinical features and outcomes of FSGS
have not taken these morphologic variants of FSGS into
consideration.
Studies that attempted to determine the clinical impor-
tance of different structural variants of FSGS are complicated
by the lack of standardized definitions for these pathologic
variants. Recently, a group of renal pathologists proposed a
standardized pathologic classification system for FSGS.13,14
Five categories were defined: collapsing variant of FSGS
(collapsing FSGS), tip lesion variant of FSGS (tip lesion
FSGS), cellular variant of FSGS (cellular FSGS), perihilar
variant of FSGS (perihilar FSGS), and FSGS not otherwise
specified (FSGS NOS) (Figure 1).
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Two recent studies have described the clinical character-
istics and renal outcomes of patients with FSGS using the
new pathologic classification.8,15 These studies compared
some but not all five of the FSGS variants. The current study
utilized a large cohort of FSGS patients to determine if the
pathologic variants defined by the Columbia proposal14 are
distinct clinical and pathologic entities. Pathologic specimens
and clinical data from the Glomerular Disease Collaborative
Network patient registry were reviewed and the clinical
outcomes and response to treatment were compared across
the FSGS subtypes.
RESULTS
A total of 282 patients were enrolled into the registry. Eighty-
five patients were not eligible for this evaluation owing to age
less than 21 years (N¼ 39) or presence of less than 5
glomeruli per level of section on biopsy or missing slides
(N¼ 46). In the remaining 197 patients, the frequency of the
variants was: 3% cellular FSGS (N¼ 6), 11% collapsing FSGS
(N¼ 22), 17% tip lesion FSGS (N¼ 34), 42% NOS FSGS
(N¼ 83), and 26% perihilar FSGS (N¼ 52). As so few
patients were identified with cellular FSGS, data for this
group are presented but not included in the statistical
comparisons among variants.
As expected, nephrotic syndrome, hypertension, and renal
insufficiency were commonly seen in all variants at
presentation (Table 1). After a median follow-up of 1.8 years
(range 0–16 years), 45 (23%) patients were on dialysis and 56
(28%) were either on dialysis or had doubled their serum
creatinine. Thirty-eight patients (19%) had a complete
remission and nine (5%) had partial remission of the
nephrotic syndrome at follow-up (Table 1). Partial remission
was achieved in one patient with collapsing FSGS, two
patients with FSGS NOS, five patients with perihilar FSGS,
and one patient with tip lesion FSGS.
One hundred and thirty-nine patients (71%) were treated
with angiotensin-converting enzyme inhibitors or angioten-
sin-receptor blockers during follow-up. Treatment with
angiotensin-converting enzyme inhibitors or angiotensin-
receptor blockers was not associated with remission of
the nephrotic syndrome (P¼ 0.11). Sixty-seven patients
(34%) received corticosteroid treatment at a mean predni-
sone-equivalent dose of 63717 mg/day for an average of
8.677 months. Patients with the tip lesion FSGS were more
often treated with corticosteroids and those with the
collapsing variant were less likely compared to other variants
(62% tip lesion, 14% collapsing, 35% perihilar, 37% NOS,
P¼ 0.003). Overall, treatment with corticosteroids was
significantly associated with remission (P¼ 0.007). Complete
remission was seen in 20 of 67 (30%) patients taking
corticosteroids and seven of 58 (14%) of those not treated
with corticosteroids. After adjusting for corticosteroid
exposure, complete remission was still significantly
higher for tip FSGS compared to other variants
(Po0.001). However, use of corticosteroid therapy was not
associated with better renal survival (P¼ 0.10). Only 8% of
the patients received additional immunosuppressive
therapy: six received cyclophosphamide, 10 cyclosporine,
two either mycophenolate mofetil or azathioprine, and
one fish oil.
Focal segmental glomerulosclerosis, collapsing
variant:
• Pre-empts other variants.
• At least one glomerulus with defining
features.
• Defining features: 
o Glomerular capillary tuft collapse. 
o Overlying podocyte hypertrophy and
hyperplasia.
 
• Other glomeruli may have segmental
lesions of any subclass.
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Focal segmental glomerulosclerosis, tip
variant:
• Exclude FSGS, collapsing variant.
• At least one glomerulus with defining
features.
• Defining features:
o Origin of proximal tubule
must be identified.
o Segmental lesion involves the
glomerular 'tip domain (outer
25% of glomerular tuft)'.
o Adhesion or confluence of
glomerular tuft lesion in the
'tip domain' with the
identified origin of the
proximal tubule.
o Lesion in 'tip domain'  may
be foam cells or endocapillary
hypercellularity (<50% of
glomerular tuft), or sclerosis
(< 25% of glomerular tuft).
o Presence of 'perihilar lesion'
rules out FSGS, tip variant.
Focal segmental glomerulosclerosis,
perihilar variant:
• Exclude FSGS, collapsing variant,
exclude FSGS, tip variant, and
exclude FSGS, cellular variant.
• More than 50% of glomeruli must 
have the defining features.
• Defining features: 
o At least one glomerulus must
have perihilar hyalinosis.
o More than 50% of glomeruli 
with segmental lesions must 
have perihilar sclerosis.
Focal segmental glomerulosclerosis, not otherwise specified (NOS):
• Exclude FSGS, collapsing variant, exclude FSGS, tip variant, exclude FSGS, cellular
variant, and exclude FSGS, perihilar. 
• Segmental glomerular capillary tuft lesion.
• Defining features: 
o May be segmental capillary wall collapse (without podocyte hyperplasia), segmental
sclerosis (peripheral or perihilar).
o Any number of glomeruli are involved.
Focal segmental glomerulosclerosis, cellular
variant:
• Exclude FSGS, collapsing variant AND
exclude FSGS, tip variant.




typically expansive and foam cells, 
in any segment of glomerular
capillary tuft (at least 25%), with
capillary lumen occlusion.






Figure 1 | Columbia FSGS classification system. Pictures are
representative images of FSGS variants: (a) collapsing FSGS, (b) tip
FSGS, (c) cellular FSGS, and (d) perihilar FSGS.
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The sociodemographic, clinical presentation, and patho-
logic findings across the different variants of FSGS are
discussed below.
Collapsing FSGS
Collapsing FSGS had a striking pre-dilection for African-
Americans and typically presented with severe nephrotic
syndrome (mean proteinuria 410 g/day) and substantial
renal insufficiency, as has been reported in earlier stu-
dies10,11,15 (Table 1). There was no sex pre-dilection. These
patients were on average younger than patients with the other
FSGS variants, although all variants had a wide age range.
Collapsing FSGS patients had the worst 1-year (74%) and
3-year (33%) renal survival (Figure 2), and only 14% of
patients were in complete remission at the end of follow-up.
Pathologically, collapsing FSGS had the highest total injury
score with the highest levels of injury in glomeruli, tubules,
and interstitium, but this was not statistically significant
(Table 2). Thus, differences in the histologic severity of injury
in collapsing FSGS did not explain the markedly worse
prognosis and supports the possibility that the nature of the
injury was inherently different.
Tip lesion FSGS
Tip lesion FSGS patients had a disproportionately low
percentage of African-Americans (15%), which is in striking
contrast to the increased proportions of African-Americans
with collapsing FSGS (91%). Tip lesion FSGS patients usually
presented with severe nephrotic syndrome with a mean 24 h
urine protein of 9.7 g, mean serum albumin of 2.5 g/dl, and
mean serum cholesterol of 359 mg/dl (Table 1). Although
both tip lesion FSGS and collapsing FSGS presented with
more frequent and more severe nephrotic syndrome than
other variants of FSGS, the initial and final renal function was
least impaired in tip lesion FSGS patients and most severely
Table 1 | Demographics, clinical presentation, and outcomes of focal segmental glomerulosclerosis variants













Age 49715 45713 38712a 54713 50716 50715 0.0009
(range) (23–89) (30–61) (24–73) (28–73) (23–89) (23–81)
Male (%) 55 67 45 50 56 58 0.70
Black (%) 40 33 91b 15b 29 43 o0.001
Nephrotic syndrome (%) 70 75 83 88 55c 67 0.01
Hypertension (%) 74 75 67 54 80 80 0.05
MAP (mmHg) 107714 110710 106713 111716 105714 107713 0.30
Serum creatinine (mg/dl) 2.172.0 2.571.7 3.173.8 1.570.9d 2.071.4 2.171.8 0.02
Serum albumin (g/dl) 3.170.9 2.870.9 2.571.0b 2.570.9b 3.770.6 3.270.8 o0.0001
Cholesterol (mg/dl) 2897127 2787184 2807132 3597141 242768 2837130 0.14
Proteinuria (g/day) 6.874.9 16715 10.075.3b 9.777.0b 4.473.3 5.574.6 o0.001
Median (inter-quartile range) 5(3–9) 14 (7–26) 12 (4–15) 7(5–12) 4 (2–6) 5 (3–7)
Complete remissione (%) 19 33 14 50f 10 13 o0.0001
Partial or complete remissione (%) 24 33 18 53f 19 16 o0.0001
1-year renal survival (%) 86 83 74 88 89 86 —g
3-year renal survival (%) 67 NA 33 76 75 65 —g
MAP=mean arterial pressure; NA=not available; NOS=not otherwise specified.
Note: Test does not include cellular FSGS variant.
Numbers are mean7s.d. or percentages, unless stated.
aCollapsing vs others.
bCollapsing, Tip vs Perihilar, NOS.
cPerihilar vs tip and collapsing.
dTip vs Collapsing.
ePatients with less than 0.5 mg/dl increase in serum creatinine at follow-up.
fTip vs others.
gSee survival analysis (figure).
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Figure 2 | Renal survival of patients with focal segmental
glomerulosclerosis by variant subtype. P¼ 0.0016 by the log-rank
test. Numbers below the table represent patients at risk at each time
point.
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impaired in collapsing FSGS patients. Of all FSGS variants,
tip lesion FSGS patients had the highest rate of complete
remission (50%) and the highest rate of renal survival at 3
years (76%) and 5 years (76%) (Figure 2). After adjusting
for corticosteroid exposure, complete remission was still
significantly higher for tip lesion FSGS compared to other
variants (Po0.001). In accord with the better preservation of
renal function, pathologic evaluation revealed the least severe
tubulointerstitial injury and total injury score in patients
with tip lesion FSGS (Table 2). Tip lesion patients also had
the least severe arteriosclerosis even though these patients
were on average older than the other groups. This finding is
in line with the clinical observation that tip lesion FSGS
patients had the lowest frequency of hypertension.
Perihilar FSGS
Patients with perihilar FSGS had the lowest frequency of
nephrotic syndrome (55%) and the highest frequency of
hypertension (80%) (Table 1). At presentation, they had
slightly lower mean serum albumin (3.7 g/dl), lowest mean
serum cholesterol (242 mg/dl), and lowest mean 24 h urine
protein (4.4 g). These patients had the lowest serum
creatinine at presentation and a low rate of complete and
partial remission (around 10% for each); they had good renal
survival at 1 year (89%) and 3 years (75%) (Figure 2).
Perihilar FSGS did not have a pre-dilection for African-
Americans.
Cellular FSGS
Given the low frequency of the cellular FSGS as defined by
the Columbia system, no conclusions could be reached about
its typical clinical features or outcomes.
NOS FSGS
Patients with FSGS NOS tended to have clinical and
pathologic parameters that were intermediate with respect
to the spectrum of findings in the other distinctive variants,
although this group was most similar to the perihilar FSGS
group (Tables 1 and 2). Hypertension (80%) and nephrotic
syndrome (67%) were common. Complete remission was low
at 13%, and renal survival at 3 years was 65% (Figure 2).
Pathologic evaluations indicated that this variant probably is
not merely an advanced phase of the other distinctive
variants because glomerular sclerosis and chronic tubuloin-
terstitial injury were not particularly severe.
DISCUSSION
The data on idiopathic FSGS in adults encompass a
pathologically diverse group of diseases with different
demographic characteristics, clinical manifestations, and
outcomes. The most striking demographic finding was the
markedly increased proportion of African-Americans with
collapsing FSGS (91%) and substantially lower proportion of
African-Americans with tip lesion FSGS (15%). At presenta-
tion, collapsing FSGS and tip lesion FSGS usually had severe
nephrotic syndrome with mean 24 h protein excretions of
10.0 and 9.7 g/day, respectively, whereas perihilar FSGS and
FSGS NOS had less proteinuria with mean 24 h protein
excretions of 4.4 and 5.5 g/day, respectively. Although
collapsing FSGS and tip lesion FSGS presented with similarly
severe proteinuria, the outcomes were dramatically different.
Collapsing FSGS had a low complete remission rate (14%)
and low 3-year renal survival (33%), whereas tip lesion FSGS
had the highest complete remission rate (50%) and the best
3-year renal survival (76%). In addition to less severe
nephrotic syndrome, perihilar FSGS and FSGS NOS tended
to have more hypertension clinically and more arteriosclero-
sis pathologically.
Two recent papers studied clinical–pathologic correlates of
patients with FSGS utilizing this working proposal of the
morphologic classification of FSGS.8,15 An analysis of 47
patients with tip lesion FSGS showed that patients were
predominantly Caucasians and often had nephrotic syn-
drome and severe proteinuria at presentation, similarly to
patients in our study.8 In addition, patients often had mild
histologic features and preserved renal function. Of 29
patients with follow-up, 59% achieved complete remission of
nephrotic syndrome at a mean follow-up of 21.5 months and
one lost renal function.8 The study by Chung et al. compared
three FSGS variants, but only two of the variants were defined
using the Columbia working proposal criteria.15 Similar to
our results, these patients with tip lesion FSGS and ‘cellular
Table 2 | Pathologic findings in renal biopsy of focal segmental glomerulosclerosis variants
Focal segmental glomerulosclerosis variants (N=197)
Pathology findings Cellular (N=6) Collapsing (N=22) Tip (N=34) Perihilar (N=52) NOS (N=83) P-value
Glomerular sclerosis/consolidation (0–4) 1.371.0 2.071.0 0.870.5a 1.971.0 1.871.0 o0.0001
Interstitial fibrosis (0–4) 1.971.0 2.170.9 0.970.7a 2.070.9 2.071.0 o0.0001
Tubular atrophy/injury (0–4) 1.971.0 2.270.9 0.970.7a 2.070.9 1.971.0 o0.0001
Interstitial leukocytes infiltration (0–4) 0.870.3 1.570.8 0.570.5a 1.270.8 1.270.8 o0.0001
Arteriosclerosis (0–4) 1.471.1 1.271.2b 0.870.9b 1.871.0 1.971.1 o0.0001
Total injury score (0–16)c 5.272.8 6.372.7 2.571.5a 5.972.6 5.672.9 o0.0001
NA=not available; NOS=not otherwise specified.
Note: A minimum of five glomeruli was required for inclusion in the study. Cellular variant not included in analysis.
aTip compared to others.
bCollapsing and Tip vs Perihilar and NOS.
cSum of the scores for arteriolar, glomerular and interstitial sclerosis, and tubular atrophy.
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FSGS’ (that we call collapsing FSGS) more often had
nephrotic syndrome and low serum albumin at presentation
than those with ‘classic FSGS’. However, the degree of
interstitial fibrosis and glomerulosclerosis in their study was
not different among their three groups of patients. Five of 11
patients with tip lesion FSGS achieved complete remission
and three of 11 progressed to end-stage renal disease at a
mean of 99 months of follow-up.15
Our study showed complete remission in 50% of patients
with tip lesion FSGS, similar to the above studies. These
patients had mild chronic histologic features compared to
other variants. However, we were not able to show a renal
survival advantage comparing patients with tip lesion FSGS
and those with perihilar FSGS and FSGS NOS.
The current study does not define the relative frequency of
various FSGS categories because of sampling techniques used
that caused a selection bias in favor of patients with
collapsing and tip lesion FSGS. These patients more often
present with nephrotic syndrome or increased creatinine,
and, therefore, they are more likely to have a kidney biopsy,
an inclusion criterion for our study. However, the low
frequency of cellular FSGS as defined by the Columbia
classification system in our study and others15 raises the
issue of whether or not this is a distinctive category of
FSGS. The hallmark of the cellular lesion as defined by
the Columbia classification, endocapillary foam cells, can
be seen in the other variants of FSGS and are particularly
conspicuous in many examples of tip lesion FSGS. One
possibility is that some lesions that would fulfill the
criteria for cellular FSGS are, in fact, advanced stages of tip
lesion FSGS in which the cellular consolidation has
spread from the tip to involve a greater portion of the
glomerular tuft.
The argument has been raised that the various structural
appearances observed in FSGS are merely random patterns of
injury that do not define distinct subsets of patients with
different disease processes. The data in this study do not
support this argument because of the significant differences
in demographics, clinical presentation, and outcomes that
correlate with the different patterns of injury. In addition, the
pathologic findings on the initial renal biopsy specimens do
not support the concept that these different histologic
appearances represent different temporal phases in the
evolution of the injury because there was no clear progression
of chronicity among the groups.
Further support for the distinctiveness of the pathologic
variants and for the possibility that they result from different
etiologies and pathogenic mechanisms is provided by the
correlation of these variants with specific forms of secondary
FSGS. For example, known secondary causes of FSGS
including human immunodeficiency virus-associated FSGS16
and most FSGS caused by pamidronate17 manifest as
collapsing FSGS and not as tip lesion FSGS or perihilar
FSGS. Likewise, perihilar FSGS is the typical glomerular
injury caused by obesity18 or reduced renal mass.19,20 Thus,
recognized causes of FSGS usually produce specific patterns
of injury that correspond to histologic variants in patients
with idiopathic FSGS, which supports the concept that these
variants are not random variations caused by a common
pathogenic mechanism, but rather are the result of different
etiologies.
The recognition of distinctive variants of disease that are
subsumed under the imprecise term FSGS is only a first step
toward recognizing etiologically and pathogenetically distinct
variants of FSGS, so that appropriate prevention and
treatment can be identified.
MATERIALS AND METHODS
Study design and population
A cohort of adult patients with biopsy-proven idiopathic FSGS
diagnosed between March 1982 and July 2001 within the
Glomerular Disease Collaborative Network (GDCN) was evaluated.
The GDCN is a consortium of over 200 nephrologists from
throughout the southeastern United States who submit renal biopsy
specimens to the University of North Carolina Nephropathology
Laboratory. Since 1998, the GDCN has been actively recruiting both
prospective and retrospective diagnoses for an ongoing FSGS
registry. Clinical data is prospectively gathered from the time of
renal biopsy diagnosis until the patient reaches end-stage renal
disease or dies. Patients were eligible for the current study if they
were older than 21 at the time of renal biopsy and signed an
informed consent for participation in the registry.
Patients with sickle cell disease, reflux nephropathy, single
kidney, human immunodeficiency virus infection, and a documen-
ted history of sleep apnea were excluded by review of the medical
records. Obesity was not an exclusion criterion in this study because
patient weights were most often measured at disease presentation
when patients frequently had nephrotic syndrome with significant
edema, which prevented reliable estimates of body mass index.
Patients with FSGS in renal transplant biopsies were also excluded.
Renal biopsies containing less than five glomeruli per level of section
in light microscopy were excluded. The study was approved by the
Committee on the Protection of the Rights of Human Subjects at the
University of North Carolina.
Kidney biopsy methods
Kidney biopsy specimens were evaluated by (1) light microscopy on
formalin–fixed, paraffin-embedded tissue using hematoxylin and
eosin, periodic acid Schiff, and Masson trichrome staining; (2)
immunofluorescence microscopy on frozen tissue using fluorescei-
nated antibodies to immunoglobulin (Ig)G, IgA, IgM, kappa light
chains, lambda light chains, C3, C1q, and fibrin; and (3)
transmission electron microscopy on tissue fixed in 2.5%
gluteraldehyde and plastic embedded. Patients with any of the
structural expressions of FSGS were entered into the registry.
Pathologic findings in the vascular, glomerular, and interstitial
compartments, including arteriosclerosis, glomerular sclerosis,
interstitial fibrosis, interstitial leukocyte infiltrate, and tubular
injury or atrophy, were scored using a semiquantitive scale
of 0¼ normal, 1¼mild, 2¼moderate, 3¼moderately severe,
and 4¼ severe. A global chronicity score was calculated by the
sum of the individual scores for arteriosclerosis, glomerular
sclerosis, interstitial fibrosis, and tubular atrophy with a maximum
score of 16.
The renal biopsy materials were categorized according to the
Columbia FSGS classification system13 independently by the study
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pathologists, DBT and JCJ. A summary of the classification system is
included in Table 1. Renal biopsy review was carried out without the
knowledge of clinical outcomes. Agreement in diagnosis was 97%.
In the remaining 3% of cases (N¼ 6), agreement was reached by a
second review of the slides.
Classification of FSGS
Major histologic criteria for the five FSGS variants are summarized
below and representative images provided in Figure 1. All variants
had segmental consolidation of some glomeruli that was either
predominantly sclerotic or cellular. Glomerular sclerosis was defined
as the extracellular accumulation or condensation of matrix that
impinged on or obliterated capillary lumens.
‘Cellular’ variants of FSGS have been recognized for decades.21
However, the term ‘cellular FSGS’ has been used for distinctly
different patterns of glomerular injury. This likely has led to the
description of different clinical presentations and outcomes in the
literature.15,21 In the current study, we use the Columbia classifica-
tion system in which the two variants of FSGS with the most
conspicuous ‘cellularity’ are divided into ‘cellular’ variant of FSGS
and ‘collapsing’ variant of FSGS. The increased cellularity in cellular
variant of FSGS as defined by the Columbia system is caused by
endocapillary hypercellularity (inside the glomerular basement
membrane) usually with foam cells (Figure 1c). Whereas in the
collapsing variant of FSGS, the increased cellularity is caused by
extracapillary hypercellularity outside the glomerular basement
membrane caused by epithelial hypertrophy and hyperplasia (Figure
1a). The tip lesion variant of FSGS also often but not always has
segmental increased cellularity caused by a combination of
endocapillary foam cells and hypertrophied epithelial cells that are
in segments contiguous with the proximal tubular epithelial cells
(Figure 1b). Perihilar FSGS is characterized not only by the perihilar
location of lesions but also by the presence of hyalinosis (Figure 1d).
The NOS FSGS category is a nonspecific category that may include
unrecognizable stages of the other variants as well as other unrelated
disease processes that fulfill the general pathologic definition of
FSGS.
Clinical data and definitions
Medical records were reviewed for demographics and clinical
findings at renal biopsy and at 3-month (71 month) intervals of
follow-up. Data were collected on disease presentation, co-
morbidities, medications, and findings by physical examination.
Information was also recorded on FSGS treatment, use of
antihypertensive agents, and renal and patient outcomes including
the outcome of the nephrotic syndrome, initiation of dialysis,
receiving a kidney transplant, or death. Serum creatinine, albumin
and cholesterol, and urinary protein excretion were recorded when
available.
Nephrotic syndrome was defined as urinary protein excretion
higher or equal to 3.5 g/day associated with serum albumin of less
than 3.5 g/dl. Complete remission was considered as a reduction in
proteinuria to less than or equal to 0.6 g/24 h with stable serum
creatinine (not more than 25% increase in serum level between
biopsy diagnosis and each proteinuria evaluation). Partial remission
was defined as a reduction in proteinuria to less than 3.5 g and
higher than 0.6 g/24 h, and stable renal function in patients
presenting with nephrotic syndrome. Renal failure was defined as
a sustained doubling of the serum creatinine, or by initiation of
chronic dialysis or kidney transplantation.22 Hypertension was
defined as a blood pressure of 130/90 mmHg or higher or the use of
antihypertensive drugs.
Statistical analysis
Demographics, pathologic parameters, and clinical and laboratory
findings at renal biopsy and follow-up were evaluated across FSGS
subtypes using a continuity adjusted w2 test or Fisher exact test, as
required by the available sample size and frequency distribution.
Continuous variables were compared between subgroups of FSGS
using analysis of variance or a log-rank test for variables, if
assumptions for analysis of variance were not met. As this was
considered an exploratory hypothesis generating analysis and not a
hypothesis testing analysis, an adjustment for multiple testing was
not carried out and a P-value of o0.05 was considered statistically
significant. Results are reported as means7standard deviation (s.d.).
Kaplan–Meier renal survival estimates were calculated and a log-rank
test was used to compute a non-parametric test for inequality of
survival curves between groups. Analysis was performed using SAS
version 8.1 statistical software (SAS Institute, Cary, NC, USA).
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